ID   KTA-2
AC   CVCL_9573
SY   KTA2; KTA-II
DR   CGH-DB; 50-1
DR   RCB; RCB5471
DR   Wikidata; Q54900614
RX   Patent=US8029793;
RX   PubMed=8121182;
RX   PubMed=9177455;
RX   PubMed=15613457;
RX   PubMed=16924234;
CC   Group: Patented cell line.
CC   Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-7525.
CC   Population: Japanese.
CC   Doubling time: 63.1 hours (PubMed=8121182).
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: In situ; Thyroid gland; UBERON=UBERON_0002046.
DI   NCIt; C3878; Thyroid gland anaplastic carcinoma
DI   ORDO; Orphanet_142; Anaplastic thyroid carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   80Y
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 29-06-23; Version: 18
//
RX   Patent=US8029793;
RA   Yoshida A., Yanoma S., Hirose F.;
RT   "Methods for inhibiting cell proliferation.";
RL   Patent number US8029793, 04-Oct-2011.
//
RX   PubMed=8121182; DOI=10.1002/jso.2930550209;
RA   Yoshida A., Asaga T., Masuzawa C., Kawahara S., Yanoma S., Harada M.,
RA   Okamoto T.;
RT   "Production of cytokines by thyroid carcinoma cell lines.";
RL   J. Surg. Oncol. 55:104-107(1994).
//
RX   PubMed=9177455; DOI=10.1016/S0304-3835(97)04742-3;
RA   Satake S., Sugawara I., Watanabe M., Takami H.;
RT   "Lack of a point mutation of human DNA topoisomerase II in
RT   multidrug-resistant anaplastic thyroid carcinoma cell lines.";
RL   Cancer Lett. 116:33-39(1997).
//
RX   PubMed=15613457; DOI=10.1677/erc.1.00818;
RA   Onda M., Emi M., Yoshida A., Miyamoto S., Akaishi J., Asaka S.,
RA   Mizutani K., Shimizu K., Nagahama M., Ito K., Tanaka T., Tsunoda T.;
RT   "Comprehensive gene expression profiling of anaplastic thyroid cancers
RT   with cDNA microarray of 25 344 genes.";
RL   Endocr. Relat. Cancer 11:843-854(2004).
//
RX   PubMed=16924234; DOI=10.1038/sj.onc.1209899;
RA   Yu W., Imoto I., Inoue J., Onda M., Emi M., Inazawa J.;
RT   "A novel amplification target, DUSP26, promotes anaplastic thyroid
RT   cancer cell growth by inhibiting p38 MAPK activity.";
RL   Oncogene 26:1178-1187(2007).
//